74 results
Page 2 of 4
8-K
EX-99.1
1oo6s5l84yg2u1qxq6
4 May 23
Regulation FD Disclosure
9:25am
8-K
otd2gwjo1u6 i4w
4 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
10-K
65j1f3 zx
17 Apr 23
Annual report
4:06pm
6-K
EX-99.1
vw4rzb
29 Dec 22
Report of Foreign Private Issuer
10:39am
6-K
EX-1.1
k8rxt4aoce7pty
20 Dec 22
BiondVax Announces Closing of $8 Million Underwritten Public Offering
5:29pm
F-1/A
EX-1.1
gszml5bf2nxcbgbaq
14 Dec 22
Registration statement (foreign) (amended)
4:45pm
F-1/A
EX-10.14
4os 9zvhz6blbx58i8ky
14 Dec 22
Registration statement (foreign) (amended)
4:45pm
6-K
EX-99.1
fdgepl6
10 Nov 22
Current Report
5:28pm
F-1
EX-10.14
q4e zk78j
29 Sep 22
Registration statement (foreign)
9:22am
6-K
EX-99.1
s68adoxwzcm
11 Jan 22
Report of Foreign Private Issuer
6:06am
6-K
EX-99.2
oazrv 2t21xwlwofqq
30 Dec 21
Former CFO of GSK’s Global Vaccines Business Mr. Jay Green Joins BiondVax’s Board of Directors
4:15pm
6-K
EX-1.1
xx2r5gp
29 Dec 21
Report of Foreign Private Issuer
6:06am
424B5
3n5a 7utv1im5
28 Dec 21
Prospectus supplement for primary offering
5:20pm
6-K
EX-99.1
obv 208du1
27 Dec 21
BiondVax Announces Pricing of $9.0 million Follow-on Underwritten Offering of American Depositary Shares
4:15pm
424B5
yrok94y 4vc
27 Dec 21
Prospectus supplement for primary offering
6:22am
6-K
EX-99.1
47iimr5 yl
11 Feb 21
BiondVax Announces Exercise in Full of Underwriter’s Over-Allotment Option in Follow-on Offering
6:30am